Key Highlights
- C4 Therapeutics (NASDAQ:CCCC) is listed at USD 2.83, which is 67% above its 52-week low of USD 1.69 and 45.3% below its high of USD 5.17.
- C4 Therapeutics presented new biomarker data for cemsidomide, an oral IKZF1/3 degrader for multiple myeloma, at the International Myeloma Society meeting after a September 3 announcement.
- The company is enrolling a Phase 2 MOMENTUM trial and a Phase 1b trial combining cemsidomide with elranatamab, and it expanded its Roche partnership for degrader antibody conjugates.
- The stock fell 7.68% to USD 2.83 on a market value of USD 350.622 million, within a range of USD 1.69 to USD 5.17.
The Latest Verified Updates
No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. C4 Therapeutics develops targeted protein degraders, and its lead drug cemsidomide is an oral molecular glue degrader of IKZF1 and IKZF3 being tested in relapsed or refractory multiple myeloma. On September 3 the company announced new biomarker data on cemsidomide's immunomodulatory effects with dexamethasone at the 23rd International Myeloma Society meeting, and in June it presented Phase 1 data at EHA 2026. It reported second-quarter results on August 11 and has a Phase 2 MOMENTUM trial and a Phase 1b combination trial with elranatamab enrolling.
Short Interest, Volume and the Data
The company expanded its long-term Roche partnership with a new collaboration on degrader antibody conjugates, which adds non-dilutive funding potential. The price of USD 2.83 is about 45% below the USD 5.17 high and 67% above the USD 1.69 low, simple arithmetic. Volume of 2.828 million shares is about 1.2 times average, and the stock appears among the most shorted names on the screen. Simple arithmetic puts the prior close near USD 3.07, so the day's move is about USD 0.24 a share. The price sits 67% above its 52-week low and 45.3% below its high, which frames how much of the range has already been used. Volume of 2.828 million shares against a three-month average of 2.383 million is 1.2 times, which is close to average; in a heavily shorted stock, high volume can reflect short covering or new short selling, so volume alone does not reveal direction.
Risks and What to Watch
Clinical data risk in multiple myeloma, competition and the need for additional capital keep the stock volatile. What to watch next: MOMENTUM trial progress, combination data and cash runway. This is information only and not investment advice. Oil traded above USD 100 a barrel as Russia-Ukraine and Middle East developments and stalled Strait of Hormuz talks kept supply risks elevated. The big banks are reporting this week, with Bank of America and Morgan Stanley on October 14 and September CPI data due the same day. The Fed raised rates in September and meets again on October 27 and 28, and the 10-year Treasury yield touched about 5.35% on October 7, the highest since 2002.
Where Things Stand
Market conditions frame the day: oil traded above USD 100, the big banks report this week and heavily shorted technology names remain volatile. C4 Therapeutics (NASDAQ:CCCC) is moving with clinical-stage trading with fresh biomarker data. A drop in a heavily shorted stock can reverse quickly, so the balance of evidence favors waiting for confirmation from filings and the next session. Direction remains unknown, and the next catalyst is MOMENTUM trial progress, combination data and cash runway. Check the underlying filings first, verify the latest filings before acting, and treat the figures as a snapshot.






Please wait processing your request...